NASDAQ: APGEApogee Therapeutics Inc Stock
$132.91+0.14 (+0.11%)
Updated Jul 2, 2026
APGE Price
$132.91
Fair Value Price
$2.02
Market Cap
$10.02B
52 Week Low
$34.34
52 Week High
$133.85
P/E
-30.7x
P/B
7.98x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$274.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$235M
Beta
1.23
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
APGE Overview
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APGE's potential to beat the market
- APGE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APGE
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important APGE news, forecast changes, insider trades & much more!
APGE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APGE ($132.91) is overvalued by 6,474.1% relative to our estimate of its Fair Value price of $2.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
APGE ($132.91) is not significantly undervalued (6,474.1%) relative to our estimate of its Fair Value price of $2.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
APGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APGE due diligence checks available for Premium users.
Valuation
APGE fair value
Fair Value of APGE stock based on Discounted Cash Flow (DCF)
Price
$132.91
Fair Value
$2.02
Overvalued by
6,474.10%
APGE ($132.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APGE ($132.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-30.7x
Industry
17.59x
Market
8.54x
APGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.98x
Industry
5.6x
APGE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APGE's financial health
Profit margin
Revenue
$0.0
Net Income
-$74.1M
Profit Margin
0%
APGE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$37.9M
Debt to equity
0.03
APGE's short-term assets ($1.07B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APGE's short-term assets ($1.07B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$55.6M
Investing
-$35.3M
Financing
$411.2M
APGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APGE vs Biotech Stocks
Apogee Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.